These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 25923229)

  • 21. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
    Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
    J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.
    Oh HS; Lee DH; Seo JY; Cho YR; Kim N; Jeoung SH; Kim JW; Hwang JH; Park YS; Lee SH; Shin CM; Cho HJ; Jung HC; Song IS
    J Gastroenterol Hepatol; 2012 Mar; 27(3):504-9. PubMed ID: 21916989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.
    Cao Z; Chen Q; Zhang W; Liang X; Liao J; Liu W; Xiao S; Lu H
    Scand J Gastroenterol; 2015; 50(10):1185-90. PubMed ID: 25881966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
    Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
    Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
    Zheng Q; Pan Y; Zhang L; Xiao SD
    Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies.
    Aktaş B; Başyiğit S; Yüksel O; Akkan T; Atbaşı ST; Uzman M; Yılmaz B; Şimşek G; Nazlıgül Y
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):769-75. PubMed ID: 25919773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
    Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
    Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
    Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori.
    Wu TS; Hsu PI; Kuo CH; Hu HM; Wu IC; Wang SSW; Chen YH; Wu DC; Su WW; Kuo FC
    J Dig Dis; 2017 Sep; 18(9):537-542. PubMed ID: 28644575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication.
    Gao XZ; Qiao XL; Song WC; Wang XF; Liu F
    World J Gastroenterol; 2010 Sep; 16(34):4357-62. PubMed ID: 20818821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication].
    Kwon S; Lee DH; Kang JB; Kim N; Park YS; Shin CM; Yoon H; Choi YJ
    Korean J Gastroenterol; 2018 Apr; 71(4):196-203. PubMed ID: 29684968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
    Avşar E; Tiftikçi A; Poturoğlu S; Erzin Y; Kocakaya O; Dinçer D; Yıldırım B; Güliter S; Türkay C; Yılmaz U; Onuk MD; Bölükbaş C; Ellidokuz E; Bektaş A; Taşan G; Aytuğ N; Ateş Y; Kaymakoğlu S
    Turk J Gastroenterol; 2013; 24(4):316-21. PubMed ID: 24254262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study.
    Lim JH; Lee DH; Choi C; Lee ST; Kim N; Jeong SH; Kim JW; Hwang JH; Park YS; Lee SH; Shin CM; Jo HJ; Jang ES; Song Is; Jung HC
    Helicobacter; 2013 Jun; 18(3):180-6. PubMed ID: 23305083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Non-bismuth quadruple therapy versus standard triple therapy for Helicobacter pylori eradication: a randomized controlled study].
    Wang S; Wang W; Chu Y; Teng G; Hu F
    Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(8):576-9. PubMed ID: 24762684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.
    Long X; Chen Q; Yu L; Liang X; Liu W; Lu H
    Helicobacter; 2018 Jun; 23(3):e12485. PubMed ID: 29696736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication.
    Song Z; Suo B; Zhang L; Zhou L
    Helicobacter; 2016 Dec; 21(6):462-470. PubMed ID: 27060292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.